Published in Drug Week, April 6th, 2001
Additionally, Xanelim, also known as anti-CD11a, has demonstrated the potential for treating other inflammatory diseases.
In prior studies, Craig Leonardi, MD, Radiant Research, St. Louis, Missouri, and colleagues from throughout the United States, have found that Xanelim injected intravenously reduced lymphocyte infiltration, epidermal hyperplasia, and keratin 16 expression, which are associated with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.